Navigation Links
Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
Date:8/4/2011

alties on sales of approved products. AstraZeneca has responsibility for product commercialization, product discovery and development costs.

About the Collaboration Between AstraZeneca and Palatin Technologies

In 2007, Palatin Technologies entered into an exclusive research collaboration and license agreement with AstraZeneca to discover, develop and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes and related metabolic syndrome. Active development work by Palatin under the collaboration portion of the agreement concluded in January 2010.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor- specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin Technologies' website at www.palatin.com .

Forward-looking Statements

Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc. such as statements about clinical trial results, potential actions by regulatory agencies including the U.S. Food and Drug Administration (FDA), regulatory plans, development programs, proposed indications for product candidates and market potential for product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby.  Such forwa
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal
2. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
3. Palatin Technologies, Inc. Announces Results of Annual Stockholders Meeting
4. Palatin Technologies, Inc. to Present at the ROTH 23rd Annual OC Growth Stock Conference
5. Palatin Technologies, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
6. Palatin Technologies, Inc. Announces Proposed Public Offering of Common Stock and Warrants
7. Palatin Technologies, Inc. December 31, 2010 Quarter Results; Teleconference and Webcast to be Held on February 24, 2011
8. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2011 Results
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
10. Palatin Technologies, Inc. to Report Fiscal Year 2011 First Quarter Results; Teleconference and Webcast to be Held on November 16, 2010
11. Palatin Announces Strategic Realignment of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... According to Ross Selinger, President of Selinger ... the national office market continues to be strong, driven by ... by the third quarter’s surprising 3.9% GDP, unemployment decreasing to ... have held inflation down and the Fed is keeping interest ... remaining soft. , This solid economic news is having a ...
(Date:12/24/2014)... China Biologic Products, Inc. (NASDAQ: CBPO, ... integrated plasma-based biopharmaceutical company in China ... Shandong Taibang Biological Products Co. Ltd., has received ... Food and Drug Administration (the "CFDA") for its ... in the Company,s public filings, the CFDA inspected ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 /PRNewswire/ ... study of mazindol in children with attention deficit/hyperactivity disorder ... December 2014 . The paper, titled ... attention deficit/hyperactivity disorder" ( Konofal et al, ... eCollection 2014 ) shows that mazindol might be ...
(Date:12/22/2014)... 22, 2014 GenomeDx Biosciences today announced that ... Classifier, a genomic test for prostate cancer, was able ... managed by radical prostatectomy without adjuvant therapy. Although rapid ... uncommon, using tumor genomics to identify these men who ... an important advance. The study has been published ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... Finesse Solutions, LLC, a,manufacturer of measurement and control ... its new sales and service center in,Northborough, MA, in ... Solutions is converting its Irvine, CA facility to a,service ... also plans on,opening a European sales and service center ...
... MITI ), a biopharmaceutical company developing novel, ... autoimmune,diseases, today announced that it will host a ... 2008, at 9:00 am Eastern Time (2:00 pm,Central ... full year 2007,financial results. Micromet anticipates releasing its ...
... PharmAthene, Inc., a,biodefense company specializing in the ... biological threats, announced,today that it has completed the ... spectrum chemical nerve agent prophylaxis., The PK ... used the final,pegylated version of rBChE for the ...
Cached Biology Technology:Finesse Solutions Expands by Opening Sales and Service Centers 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results 2PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008 2PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008 3PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008 4
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research ... announced the addition of the "Global Facial ... http://photos.prnewswire.com/prnh/20130307/600769 ... the identification of individuals. Facial recognition system measures ... as nose, jaw edges, mouth, and the distance ...
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
(Date:12/10/2014)... -- Valencell, a leader in performance biometric data sensor technology, ... its licensees for highly accurate, clinically validated biometric technology. ... from fitness and health sectors, but first responders/military and ... only as useful as the biometric data it delivers. ... long-term mass consumer adoption of wearable products," said Dr. ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Leaders within the U.S. biomedical device industry unveiled today ... enhance the development of devices with great clinical utility, ... become a key component of the nation,s drive to ... access to device innovation that improves human health, the ...
... OF PRUSSIA, Pa., June 16, 2011 Omnicare Clinical Research, ... re-branding of the company under the name Theorem Clinical Research. ... separation from its former parent company in a deal that ... private equity firm based in Providence, R.I., acquired the CRO ...
... eruption in early June, several NASA satellites have captured images ... Volcano called Puyehue-Cordn Caulle and have tracked it around the ... image gallery that shows the progression of the plume around ... includes the Puyehue volcano, the Cordn Caulle rift zone and ...
Cached Biology News:U.S. Biomedical Leaders Present a New National Device Innovation Strategy Based on "Value-driven Engineering" 2U.S. Biomedical Leaders Present a New National Device Innovation Strategy Based on "Value-driven Engineering" 3U.S. Biomedical Leaders Present a New National Device Innovation Strategy Based on "Value-driven Engineering" 4Omnicare Clinical Research Re-Brands as Theorem Clinical Research 2Omnicare Clinical Research Re-Brands as Theorem Clinical Research 3NASA satellite gallery shows Chilean volcano plume moving around the world 2NASA satellite gallery shows Chilean volcano plume moving around the world 3
... internal standard for the quantification of 5-OxoETE ... is a polyunsaturated keto acid formed by ... It stimulates cytosolic calcium levels in neutrophils ... selectively stimulates the migration and degranulation of ...
... 4,600 to Over 3 Million Genotypes Per ... capable of performing 4,600 to over 3 ... GenomeLab family of products*, this automated, scalable, ... SNPs in each well of an arrayed ...
... These protein size markers are a mixture ... 16 to 100 kDa. The markers provide ... gels after staining with Coomassie blue. Because ... II sequence, the markers can also be ...
... solid. A nucleoside antibiotic that inhibits ... of N-glycosidic protein-carbohydrate linkages. Active ... yeasts, fungi, and viruses. Inhibits the ... human T-lymphoblastoid cells. Also inhibits thrombin-induced ...
Biology Products: